Radiotherapy of midline malignant reticulosis.
The results of radiotherapy made on 23 patients with midline malignant reticulosis showed that the 1-, 3-, 5- and 8-year survival rates were 91.3%, 63.2%, 50.0% and 40.0%, respectively. The optimum radiation dose was 50-60 Gy / 5-6 weeks. Chemotherapy with CCNU following the radiotherapy facilitated the healing of lesion, reduced local recurrence and distant metastasis, improved the therapeutic effect and raised the survival rate.
Gong
Y
Y
Department of Radiotherapy, People's Hospital of Uygur Autonomous Region, Xinjiang.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity; D009669:Nose Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D010610:Pharyngeal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000401:mortality; D011859:Radiography; D011882:Radiotherapy, High-Energy; D015996:Survival Rate
D000970:Antineoplastic Agents; D008130:Lomustine